Patents by Inventor Phillip R. Hawkins

Phillip R. Hawkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6087125
    Abstract: The present invention provides polynucleotides which identify and encode a novel human nm23-like protein (H-nm23). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding H-nm23 and for a method for producing the protein. The invention also provides for the use of substantially purified H-nm23 for the treatment of diseases associated with the expression of H-nm23. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotides which hybridize with naturally occurring sequences encoding H-nm23 and antibodies which specifically bind to the protein.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: July 11, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Phillip R. Hawkins
  • Patent number: 6080841
    Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human induced tumor protein (HITP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HITP. The invention also provides for the production and use of substantially purified HITP in pharmaceutical compositions to force differentiation and to stop cell division in cancerous cells. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding HITP and the anti-HITP antibodies which specifically bind to HITP.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: June 27, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Phillip R. Hawkins
  • Patent number: 6071701
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (ADEC) from inflamed adenoid tissue. The present invention also provides for antisense molecules to the nucleotide sequences which encode ADEC, expression vectors for the production of purified ADEC, antibodies capable of binding specifically to ADEC, hybridization robes or oligonucleotides for the detection of ADEC-encoding nucleotide sequences, genetically engineered host cells for the expression of ADEC, diagnostic tests for inflammation or disease based on ADEC-encoding nucleic acid molecules or antibodies capable of binding specifically to ADEC.
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: June 6, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Karl J. Guegler, Phillip R. Hawkins, Craig G. Wilde, Jeffrey J. Seilhamer
  • Patent number: 6060239
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel cellubrevins (cb). The present invention also provides for antisense molecules to the nucleotide sequences which encode cbs, expression vectors for the production of purified CBs, antibodies capable of binding specifically to CBs, hybridization probes or oligonucleotides for the detecting the induction of CB encoding nucleotide sequences, genetically engineered host cells for the expression of CBs, diagnostic tests for activated, inflamed or diseased cells and/or tissues based on CB-encoding nucleic acid molecules and antibodies capable of binding specifically to CBs.
    Type: Grant
    Filed: March 22, 1996
    Date of Patent: May 9, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Susan G. Stuart, Phillip R. Hawkins, Jeffrey J. Seilhamer, Lynn E. Murry
  • Patent number: 6057110
    Abstract: The present invention provides a polynucleotide (hhp) which identifies and encodes a novel human hyaluronidase (HHP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HHP. The invention also provides for the use of substantially purified HHP and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of HHP. Additionally, the invention provides for the use of antisense molecules to hhp in pharmaceutical compositions for treatment of diseases associated with the expression of HHP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of hhp. The present invention also relates to anti-HHP antibodies which specifically bind to HHP.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: May 2, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman
  • Patent number: 6054290
    Abstract: The present invention provides a human vesicle binding protein (MVBP) and polynucleotides which identify and encode MVBP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing MVBP and for treating or preventing disorders associated with expression of MVBP.
    Type: Grant
    Filed: May 15, 1997
    Date of Patent: April 25, 2000
    Assignee: Incyte Pharamaceuticals, Inc.
    Inventors: Olga Bandman, Phillip R. Hawkins, Lynn E. Murry
  • Patent number: 6045792
    Abstract: The present invention provides novel human protein kinases (HPK) and polynucleotides which identify and encode HPK. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPK. The invention also provides for pharmaceutical compositions comprising HPK or antagonists of HPK, and antibodies which specifically bind HPK. Additionally, the invention provides antisense molecules to HPK for treatment or prevention of diseases associated with abnormal expression of HPK.
    Type: Grant
    Filed: July 7, 1998
    Date of Patent: April 4, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Karl J. Guegler, Phillip R. Hawkins
  • Patent number: 6025138
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode the hyaluronan receptor (hr) from human umbilical vein endothelial cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode hr, expression vectors for the production of purified HR, antibodies capable of binding specifically to HR, hybridization probes or oligonucleotides for detecting the upregulation of HR encoding nucleotide sequences, genetically engineered host cells for the expression of HR, diagnostic tests for activated, angiogenic, inflamed or metastatic cells and/or tissues based on HR-encoding nucleic acid molecules and antibodies capable of binding specifically to the receptor.
    Type: Grant
    Filed: December 22, 1997
    Date of Patent: February 15, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Craig G. Wilde, Jeffrey J. Seilhamer
  • Patent number: 6015883
    Abstract: The present invention provides a polynucleotide (PTEC) isolated from a prostate cDNA library which identifies and encodes a novel human rantes homolog PTEC (prostate expressed chemokine). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PTEC. The invention also provides for the therapeutic use of purified PTEC in the treatment of immune deficiency diseases, and for the therapeutic use of antisense molecules, antibodies, antagonists or inhibitors in the treatment of conditions or diseases associated with the expression of PTEC. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, or fragments thereof, or antibodies which specifically bind to the polypeptide.
    Type: Grant
    Filed: September 24, 1997
    Date of Patent: January 18, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Olga Bandman, Lynn E. Murry
  • Patent number: 6015788
    Abstract: The present invention provides polynucleotides which identify and encode a novel human nucleic acid binding protein (NABP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NABP. The invention also provides for the use of substantially purified NABP or its antagonists, in pharmaceutical compositions for the treatment of diseases associated with the expression of NABP. Additionally, the invention provides for the use of antisense molecules to NABP in pharmaceutical compositions for treatment of diseases associated with the expression of NABP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding NABP or anti-NABP antibodies which specifically bind to NABP.
    Type: Grant
    Filed: November 19, 1998
    Date of Patent: January 18, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman
  • Patent number: 5981232
    Abstract: The present invention provides a human pyrophosphatase (HPYP) and polynucleotides which identify and encode HPYP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPYP and a method for producing HPYP. The invention also provides for use of HPYP and agonists, antibodies, or antagonists specifically binding HPYP, in the prevention and treatment of cancer and inflammatory diseases. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPYP for the treatment of diseases associated with the expression of HPYP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPYP.
    Type: Grant
    Filed: August 13, 1998
    Date of Patent: November 9, 1999
    Assignee: Inctye Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Jennifer L. Hillman
  • Patent number: 5977338
    Abstract: The present invention provides a novel human interferon-inducible protein (HIFI) and the polynucleotides which identify and encode HIFI. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HIFI and for a method for producing the protein. The invention also provides pharmaceutical compositions containing HIFI and the use of such compositions for the prevention or treatment of diseases associated with the expression of HIFI. Additionally, the invention provides antisense molecules to HIFI and their use in the treatment of diseases associated with the expression of HIFI. The invention also provides diagnostic assays which utilize polynucleotides which hybridize with naturally occurring sequences encoding HIFI and antibodies which specifically bind to the protein.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: November 2, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Phillip R. Hawkins
  • Patent number: 5958750
    Abstract: The present invention provides a polynucleotide (hhp) which identifies and encodes a novel human hyaluronidase (HHP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HHP, and a method for making HHP with the host cells.
    Type: Grant
    Filed: July 3, 1996
    Date of Patent: September 28, 1999
    Assignee: Inctye Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman
  • Patent number: 5955278
    Abstract: The invention provides a human translational regulator (TRANAC) and polynucleotides which identify and encode TRANAC. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of TRANAC.
    Type: Grant
    Filed: June 5, 1997
    Date of Patent: September 21, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Phillip R. Hawkins
  • Patent number: 5948626
    Abstract: The present invention provides a polynucleotide (gipl) the partial sequence for which was initially isolated from a THP-1 cDNA library and which identifies and encodes a novel human phospholipase inhibitor (GIPL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding GIPL. The invention also provides for the use of purified GIPL and its agonists in pharmaceutical compositions for the treatment of diseases associated with the abnormal or excess phospholipase activity. Additionally, the invention provides for the use of antisense molecules to gipl or inhibitors of GIPL in pharmaceutical compositions for the prevention of pregnancy or treatment of Alzheimer's disease.
    Type: Grant
    Filed: September 15, 1998
    Date of Patent: September 7, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Lynn E. Murry
  • Patent number: 5936068
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (ECs) from liver and pituitary gland tissues. The present invention also provides for antisense molecules to the nucleotide sequences which encode ECs, expression vectors for the production of purified ECs, antibodies capable of binding specifically to ECs, hybridization probes or oligonucleotides for the detection of EC-encoding nucleotide sequences, genetically engineered host cells for the expression of ECs, diagnostic tests for inflammation or disease based on on EC-encoding nucleic acid molecules or antibodies capable of binding specifically to ECs, pharmaceutical compositions to treat inflammation or disease based on EC-encoding nucleic acid molecules or antibodies capable of binding specifically to ECs.
    Type: Grant
    Filed: February 10, 1997
    Date of Patent: August 10, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Craig G. Wilde, Phillip R. Hawkins, Olga Bandman, Jeffrey J. Seilhamer
  • Patent number: 5925521
    Abstract: The present invention provides a human serine carboxypeptidase (CPEPT) and polynucleotides which identify and encode CPEPT. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of CPEPT.
    Type: Grant
    Filed: March 31, 1997
    Date of Patent: July 20, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Phillip R. Hawkins, Jennifer L. Hillman, Preeti Lal, Surya K. Goli
  • Patent number: 5922844
    Abstract: The present invention provides a polynucleotide (ipka) which identifies and encodes a novel human cAMP-dependent protein kinase A inhibitor homolog (IPKA). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding IPKA. The invention also provides for the use of purified IPKA and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of IPKA. Additionally, the invention provides for the use of antisense molecules to ipka in pharmaceutical compositions for treatment of diseases associated with the expression of IPKA. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of ipka. The present invention also relates to anti-IPKA antibodies which specifically bind to IPKA.
    Type: Grant
    Filed: July 14, 1997
    Date of Patent: July 13, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Jennifer L. Hillman, Janice Au-Young
  • Patent number: 5916556
    Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human mRNA editing enzyme (REE). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding REE. The invention also provides for the use of substantially purified REE and its agonists, antagonists, or inhibitors in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of REE. Additionally, the invention provides for the use of antisense molecules to REE in pharmaceutical compositions for treatment of diseases associated with the expression of REE. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding REE or anti-REE antibodies which specifically bind to REE.
    Type: Grant
    Filed: March 17, 1998
    Date of Patent: June 29, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman
  • Patent number: 5914392
    Abstract: The present invention provides a nucleic acid sequence which identifies and encodes a novel tissue inhibitor of metalloproteinases (TIMP-4) which was isolated from cells of human uterus. The invention provides for TIMP-4 antisense molecules and genetically engineered expression vectors and host cells comprising nucleic acid sequence encoding TIMP-4. The invention also provides for purified TIMP-4; antibodies, antagonists and inhibitors which specifically bind TIMP-4; and pharmaceutical compositions and methods of treatment based on TIMP-4, its antagonists and inhibitors. The invention provides for diagnostic assays which utilize diagnostic compositions comprising nucleic acid sequences encoding to TIMP-4, or complements thereof, and antibodies which specifically bind to TIMP-4.
    Type: Grant
    Filed: July 7, 1998
    Date of Patent: June 22, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Lynn E. Murry